2096 — Simcere Pharmaceutical Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapHigh Flyer

Annual cashflow statement for Simcere Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	805	1,402	886	740	820
Depreciation
Amortisation
Non-Cash Items	-213	-1,072	97.5	58.4	430
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-718	-784	86.7	-957	-196
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	96.7	-202	1,354	151	1,391
Capital Expenditures	-353	-209	-678	-980	-763
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	882	-226	746	2,068	-288
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	529	-436	68.3	1,088	-1,050
Financing Cash Flow Items	-996	245	-46	-35.5	934
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	2,354	-1,625	-754	-895	-407
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	2,915	-2,297	684	349	-64.1